{"prompt": "['Protocol VX18-445-109, Version 1.0', 'Page 56 of 60', 'contribution will be acknowledged and specified either as a group (e.g., \"study investigators\") or', 'individually (e.g., \"served as scientific advisor\").', 'Publication Review: As required by a separate clinical study agreement, Vertex must have the', 'opportunity to review all publications, including any manuscripts, abstracts, oral/slide', 'presentations, and book chapters regarding this study before submission to congresses or journals', 'for consideration.', '13.7.2', 'Clinical Study Report', 'A CSR, written in accordance with the ICH E3 Guideline, will be submitted in accordance with', 'local regulations.', 'Vertex Pharmaceuticals Incorporated']['Protocol VX18-445-109, Version 1.0', 'Page 57 of 60', '14', 'REFERENCES', '1', 'Cystic Fibrosis Foundation. What is cystic fibrosis? Available at:', 'https://www.cff.org/What-is-CF/About-Cystic-Fibrosis/. Accessed 22 March 2018.', '2', 'Cystic Fibrosis Foundation. Patient Registry: 2017 Annual Data Report. Bethesda, MD:', 'Cystic Fibrosis Foundation; 2018.', '3', 'European Cystic Fibrosis Society. 2016 ECFS Patient Registry Annual Data Report.', 'Karup, Denmark: European Cystic Fibrosis Society; 2018.', '4', 'United States Department of Health and Human Services. Food and Drug Administration.', 'Office of Orphan Products Development. Developing Products for Rare Diseases &', 'Conditions. Available at:', 'p://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/default.', 'htm. Accessed 19 September 2016.', '5', 'European Medicines Agency [Internet]. Committee for Orphan Medicinal Products', '(COMP). Available at: https://www.ema.europa.eu/en/committees/committee-orphan-', 'medicinal-products-comp Accessed 07 December 2018.', '6', 'Rommens J, Iannuzzi M, Kerem B, Drumm M, Melmer G, Dean M, et al. Identification', 'of the cystic fibrosis gene: chromosome walking and jumping. Science.', '1989;245(4922):1059-65.', '7', 'Kreindler JL. Cystic fibrosis: exploiting its genetic basis in the hunt for new therapies.', 'Pharmacol Ther. 2010;125(2):219-29.', '8', 'Sheppard MN, Nicholson AG. The pathology of cystic fibrosis. Curr Diagn Pathol.', '2002;8(1):50-59', '9', 'Flume PA, VanDevanter DR. State of progress in treating cystic fibrosis respiratory', 'disease. BMC Med. 2012;10(1):88.', '10', 'CFTR2.org. Clinical and functional translation of CFTR. The Clinical and Functional', 'TRanslation of CFTR (CFTR2), US Cystic Fibrosis Foundation, Johns Hopkins', 'University, the Hospital for Sick Children. Available at: http://www.cftr2.org. Accessed', '09 January 2018.', '11', 'Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, et al. Multi-ethnic', 'reference values for spirometry for the 3-95-yr age range: the global lung function 2012', 'equations. Eur Respir J. 2012;40(6): 1324-43.', '12', 'Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al.', 'Standardisation of spirometry. Eur Respir J. 2005;26(2):319-38.', '13', 'Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to', 'estimate glomerular filtration rate from serum creatinine: a new prediction equation.', 'Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130(6):461-', '70.', '14', 'Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, et al. Using', 'standardized serum creatinine values in the modification of diet in renal disease study', 'equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145(4):247-54', '15', 'Counahan R, Chantler C, Ghazali S, Kirkwood B, Rose F, Barratt TM. Estimation of', 'glomerular filtration rate from plasma creatinine concentration in children. Arch Dis', 'Child. 1976;51(11):875-78.', 'Vertex Pharmaceuticals Incorporated']['Protocol VX18-445-109, Version 1.0', 'Page 58 of 60', '16', 'Goss CH, Quittner AL. Patient-reported outcomes in cystic fibrosis. Proc Am Thorac', 'Soc. 2007;4(4):378-86', '17', 'Quittner AL, Buu A, Messer MA, Modi AC, Watrous M. Development and validation of', 'the Cystic Fibrosis Questionnaire in the United States. Chest. 2005; 128(4):2347-54', '18', 'Henry B, Aussage P, Grosskopf C, Goehrs JM. Development of the Cystic Fibrosis', 'Questionnaire (CFQ) for assessing quality of life in pediatric and adult patients. Qual Life', 'Res. 2003;12(1):63-76.', '19', 'Wenninger K, Aussage P, Wahn U, Staab D, German Cystic Fibrosis Questionnaire study', 'group. The revised German Cystic Fibrosis Questionnaire: validation of a disease-', 'specific health-related quality of life instrument. Qual Life Res. 2003;12(1):77-85.', '20', \"O'Brien PC, Fleming TR. A Multiple Testing Procedure for Clinical Trials. Biometrics.\", '1979;35(3):549-56', '21', 'Battisti WP, Wager E, Baltzer L, Bridges D, Cairns A, Carswell CI, et al. Good', 'Publication Practice for Communicating Company-Sponsored Medical Research: GPP3.', 'Ann Intern Med. 2015;163(6):461-4.', '22', '(ICMJE). ICoMJE. Recommendations for conduct, reporting, editing, and publication of', 'scholarly work in medical journals. [Internet]. Available from: Accessed April 9,.', 'Vertex Pharmaceuticals Incorporated']\n\n###\n\n", "completion": "END"}